Vish Seshadri, Abeona CEO
November 3, 2022 10:14 AM EDT
R&D

Small start­up touts a PhI­II suc­cess in rare 'but­ter­fly skin' dis­ease af­ter an FDA hold rout­ed shares

Max Gelman

Senior Editor

More than three years af­ter get­ting held up by the FDA, Abeona Ther­a­peu­tics is trum­pet­ing a da­ta drop for the rare “but­ter­fly skin” dis­ease. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

A service from the Financial Times